• Aaron R Ducoffe, Avi Baehr, Juliet C Peña, Briana B Rider, Sandra Yang, and Dale J Hu.
• US Department of Health and Human Services, Office of Disease Prevention and Health Promotion, Rockville, MD.
• Am J Med Qual. 2016 Sep 1; 31 (5): 476-85.

AbstractAdverse drug events (ADEs) have been highlighted as a national patient safety and public health challenge by the National Action Plan for Adverse Drug Event Prevention (ADE Action Plan), which was released by the Office of Disease Prevention and Health Promotion in August 2014. The following October, the ADE Prevention: 2014 Action Plan Conference provided an opportunity for federal agencies, national experts, and stakeholders to coordinate and collaborate in the initiative to reduce preventable ADEs. The single-day conference included morning plenary sessions focused on the surveillance, evidence-based prevention, incentives and oversights, and additional research needs of the drug classes highlighted in the ADE Action Plan: anticoagulants, diabetes agents, and opioids. Afternoon breakout sessions allowed for facilitated discussions on measures for tracking national progress in ADE prevention and the identification of opportunities to ensure safe and high-quality health care and medication use.© The Author(s) 2015.

18 keywords...

hide…